摘要
目的探讨EGFR、p53、Bcl-2表达,Ki-67标记指数(Ki-67Li)与胸腺瘤WHO组织学分型、分期及预后的关系。方法应用免疫组化染色方法检测46例胸腺瘤患者EGFR、p53、Bcl-2的表达和Ki-67标记指数。结果胸腺瘤EGFR、p53、Bcl-2阳性表达率分别为34.8%、56.5%、54.3%,Ki-67标记指数平均值为11.0%。EGFR、p53、Bcl-2蛋白表达与胸腺瘤WHO组织学分型均无明显关系;B2、B3、C型与A、AB、B1型之间Ki-67标记指数表达差异有显著性(P<0.05);Bcl-2蛋白表达与胸腺瘤Masaoka分期和预后均无关系(P>0.05);EGFR、p53蛋白的过度表达和Ki-67标记指数与胸腺瘤Masaoka分期明显相关(P<0.05);Ki-67标记指数与预后有关(P<0.05)。结论EGFR、p53蛋白的过度表达和Ki-67标记指数与胸腺瘤Masaoka分期明显相关,反应其侵袭性,Ki-67标记指数还与组织学分型相关,并可作为估计胸腺瘤预后的参考指标。
Objective To investigate the correlation of EGFR,p53,Bcl-2 expression and Ki-67 labeling index （Ki-67Li） with WHO histological classification, clinical stages and prognosis of patients in thymoma. Methods EGFR, p53, Bcl-2 expression and Ki-67 labeling index in tissue specimens of 46 cases with thymoma were examined immunohistochemically. Results The positive rates of EGFR,p53 and Bcl-2 in thymoma were 34.8% ,56.5% and 54.3% ,respectively. Ki-67 labeling index was 11.0%. EGFR,p53 and Bcl-2 expressions were not correlated with WHO histologic classification （P〉0. 05）. The Ki-67 labeling index expression rates of B2,B3 and C types were significantly higher than those of A,AB and B1 type in 46 thymomas （P〈0. 05）. EGFR,p53 expression and Ki-67 labeling index were correlated with clinical stages of thymoma （P〈 0. 05）. Moreover, Ki-67 labeling index was correlated with the prognosis of thymoma （P〈0.05）. Conclusions EGFR,p53 expression and Ki-67 labeling index are related to the development of thymoma and can help to differentiate invasive thymoma. The Ki-67 labeling index is also associated with WHO histological classification as a good indicator for prognosis of thymomas.
出处
《实用肿瘤杂志》
CAS
2007年第6期502-505,共4页
Journal of Practical Oncology
